<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01812005</url>
  </required_header>
  <id_info>
    <org_study_id>OSU-12106</org_study_id>
    <secondary_id>NCI-2012-02794</secondary_id>
    <nct_id>NCT01812005</nct_id>
  </id_info>
  <brief_title>Alisertib With and Without Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma</brief_title>
  <official_title>A Phase II Study of MLN8237 Alone and in Combination With Rituximab in Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ohio State University Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Millennium Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Ohio State University Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies how well alisertib with and without rituximab works in treating&#xD;
      patients with relapsed or refractory B-cell non-Hodgkin lymphoma. Alisertib may stop the&#xD;
      growth of cancer cells by blocking some of the enzymes needed for cell growth. Monoclonal&#xD;
      antibodies, such as rituximab, can block cancer growth in different ways. Some block the&#xD;
      ability of cancer cells to grow and spread. Others find cancer cells and help kill them or&#xD;
      carry cancer-killing substances to them. Giving alisertib with and without rituximab may be&#xD;
      an effective treatment for B-cell non-Hodgkin lymphoma&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To determine the efficacy of MLN8237 (alisertib) alone in patients with relapsed and&#xD;
      refractory non-Hodgkin lymphoma (NHL) and transformed NHL.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To determine the efficacy of MLN8237 when combined with rituximab in NHL patients who fail&#xD;
      to respond to MLN8237 alone in patients with relapsed and refractory NHL and transformed NHL.&#xD;
&#xD;
      II. To determine specific toxicities associated with MLN8237 alone and when combined with&#xD;
      rituximab (in NHL patients) in patients with relapsed and refractory NHL and transformed NHL.&#xD;
&#xD;
      III. To determine pharmacokinetics of MLN8237 alone and in combination with rituximab (for&#xD;
      NHL patients) in patients with relapsed and refractory NHL and transformed NHL.&#xD;
&#xD;
      IV. To evaluate specific molecular characteristics of the NHL for patients treated with&#xD;
      MLN8237 alone and with rituximab in order to correlate particular molecular markers with&#xD;
      response and survival.&#xD;
&#xD;
      V. To evaluate long term survival of patients treated with MLN8237 alone and with rituximab.&#xD;
&#xD;
      OUTLINE: Patients are assigned to 1 of 2 treatment groups.&#xD;
&#xD;
      COHORT A: Patients receive alisertib orally (PO) twice daily (BID) on days 1-7. Patients&#xD;
      unable to achieve complete response (CR) after course 4 also receive rituximab intravenously&#xD;
      (IV) on day 1 of courses 5-12. Courses repeat every 21 days in the absence of disease&#xD;
      progression or unacceptable toxicity.&#xD;
&#xD;
      COHORT B: Patients receive alisertib as in Cohort A. Patients achieving stable disease (SD)&#xD;
      or asymptomatic progressive disease after 2 courses also receive rituximab IV on day 1 of&#xD;
      courses 3-10. Patients unable to achieve CR by course 4, receive rituximab as in Cohort A.&#xD;
      Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed up every 3 months for up to 2&#xD;
      years and then every 6 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Slow patient enrollment and study discontinued after 14 patients enrolled&#xD;
  </why_stopped>
  <start_date type="Actual">May 21, 2013</start_date>
  <completion_date type="Actual">April 20, 2017</completion_date>
  <primary_completion_date type="Actual">October 14, 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Best Overall Response Rate (ORR) to Alisertib Alone</measure>
    <time_frame>Up to 18 weeks (6 courses)</time_frame>
    <description>Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>6 weeks (2 courses)</time_frame>
    <description>Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>12 weeks (4 courses)</time_frame>
    <description>95% binomial confidence intervals calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate(ORR)</measure>
    <time_frame>18 weeks (6 courses)</time_frame>
    <description>Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete Response Rate (CR)</measure>
    <time_frame>6 weeks (2 courses)</time_frame>
    <description>Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete Response Rate</measure>
    <time_frame>12 weeks (4 courses)</time_frame>
    <description>Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Time from study entry to the time of death due to any cause, assessed up to 1 year</time_frame>
    <description>Graphically summarized using the methods of Kaplan and Meier.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival</measure>
    <time_frame>Time from study entry to the time of progression and/or death, assessed up to 1 year</time_frame>
    <description>Graphically summarized using the methods of Kaplan and Meier.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete Response Rate</measure>
    <time_frame>18 weeks (6 courses)</time_frame>
    <description>Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue</condition>
  <condition>Nodal Marginal Zone B-cell Lymphoma</condition>
  <condition>Recurrent Adult Burkitt Lymphoma</condition>
  <condition>Recurrent Adult Diffuse Large Cell Lymphoma</condition>
  <condition>Recurrent Grade 1 Follicular Lymphoma</condition>
  <condition>Recurrent Grade 2 Follicular Lymphoma</condition>
  <condition>Recurrent Grade 3 Follicular Lymphoma</condition>
  <condition>Recurrent Mantle Cell Lymphoma</condition>
  <condition>Recurrent Marginal Zone Lymphoma</condition>
  <condition>Splenic Marginal Zone Lymphoma</condition>
  <condition>Waldenstr√∂m Macroglobulinemia</condition>
  <arm_group>
    <arm_group_label>Cohort A (alisertib, rituximab)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive alisertib PO BID on days 1-7. Patients unable to achieve CR after course 4 also receive rituximab IV on day 1 of courses 5-12. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B (alisertib, rituximab)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive alisertib as in Cohort A. Patients achieving SD or asymptomatic progressive disease after 2 courses also receive rituximab IV on day 1 of courses 3-10. Patients unable to achieve CR by course 4, receive rituximab as in Cohort A. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>alisertib</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Cohort A (alisertib, rituximab)</arm_group_label>
    <arm_group_label>Cohort B (alisertib, rituximab)</arm_group_label>
    <other_name>Aurora A kinase inhibitor MLN8237</other_name>
    <other_name>MLN8237</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rituximab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Cohort A (alisertib, rituximab)</arm_group_label>
    <arm_group_label>Cohort B (alisertib, rituximab)</arm_group_label>
    <other_name>IDEC-C2B8</other_name>
    <other_name>IDEC-C2B8 monoclonal antibody</other_name>
    <other_name>Mabthera</other_name>
    <other_name>MOAB IDEC-C2B8</other_name>
    <other_name>Rituxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Laboratory correlative studies will be performed</description>
    <arm_group_label>Cohort A (alisertib, rituximab)</arm_group_label>
    <arm_group_label>Cohort B (alisertib, rituximab)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Must have histologically proven relapsed or refractory B-cell NHL of the following&#xD;
             World Health Organization (WHO) classification subtypes: follicular lymphoma (FL),&#xD;
             mantle cell lymphoma (MCL), lymphoplasmacytic lymphoma/Waldenstr√∂m's macroglobulinemia&#xD;
             (LPL/WM), marginal zone lymphoma (MZL), diffuse large B-cell lymphoma (DLBCL),&#xD;
             Burkitt's lymphoma (BL), and B-cell lymphoma with features unclassifiable between&#xD;
             Burkitt's and large cell lymphoma; alternatively, patients with histologically proven,&#xD;
             newly diagnosed transformed non-Hodgkin's lymphoma (tNHL) are eligible&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-2&#xD;
&#xD;
          -  At least one prior therapy; patients with newly diagnosed tNHL are eligible and do not&#xD;
             need to have received prior therapy for the transformed lymphoma or prior indolent&#xD;
             NHL; prior autologous stem cell transplant is allowed&#xD;
&#xD;
          -  Serum creatinine =&lt; 2.0 mg/dL&#xD;
&#xD;
          -  Total bilirubin within normal limits&#xD;
&#xD;
          -  Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =&lt; 1.5 x upper limit&#xD;
             of normal&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) &gt;= 1000/ŒºL&#xD;
&#xD;
          -  Platelet count &gt;= 75,000/ŒºL&#xD;
&#xD;
          -  Recovery to =&lt; grade 1 toxicities associated with prior therapy&#xD;
&#xD;
          -  Voluntary written informed consent before performance of any study-related procedure&#xD;
             not part of normal medical care, with the understanding that consent may be withdrawn&#xD;
             by the subject at any time without prejudice to future medical care&#xD;
&#xD;
          -  Female subject is either post-menopausal or surgically sterilized or willing to use an&#xD;
             acceptable method of birth control (i.e., a hormonal contraceptive, intra-uterine&#xD;
             device, diaphragm with spermicide, condom with spermicide, or abstinence) for the&#xD;
             duration of the study&#xD;
&#xD;
          -  Male subject agrees to use an acceptable method for contraception during the entire&#xD;
             study treatment period through 4 months after the last dose of MLN8237&#xD;
&#xD;
          -  Must be able to take oral medication and to maintain a fast as required for 2 hours&#xD;
             before and 1 hour after MLN8237 administration&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or breast-feeding women and women of childbearing age who are unwilling to&#xD;
             use adequate contraception&#xD;
&#xD;
          -  Patients with a history of central nervous system involvement by lymphoma&#xD;
&#xD;
          -  Patients with known human immunodeficiency virus (HIV), hepatitis B or hepatitis C&#xD;
             (active or carriers) are not eligible; this includes all patients with a positive&#xD;
             hepatitis C antibody, hepatitis B surface antigen, or hepatitis B core antibody;&#xD;
             previously vaccinated patients with positive hepatitis B surface antibody are eligible&#xD;
&#xD;
          -  May not have received prior therapy with an Aurora kinase inhibitor&#xD;
&#xD;
          -  Patients eligible for and willing to undergo autologous stem cell transplant with&#xD;
             curative intent at the time of enrollment are not eligible; patients refractory to at&#xD;
             least 2 prior regimens may enroll and proceed to curative autologous transplant if&#xD;
             they respond&#xD;
&#xD;
          -  Patients who are on chronic steroids for unrelated conditions (i.e. rheumatologic&#xD;
             conditions) are not eligible if their total daily dose of steroids is equivalent to&#xD;
             greater than 10 mg prednisone&#xD;
&#xD;
          -  Radiation therapy to more than 25% of the bone marrow; whole pelvic radiation is&#xD;
             considered to be over 25%&#xD;
&#xD;
          -  Prior allogeneic bone marrow or organ transplantation&#xD;
&#xD;
          -  If applicable, patient has &gt;= grade 2 peripheral neuropathy within 14 days before&#xD;
             enrollment&#xD;
&#xD;
          -  Known history of uncontrolled sleep apnea syndrome and other conditions that could&#xD;
             result in excessive daytime sleepiness, such as severe chronic obstructive pulmonary&#xD;
             disease; requirement for supplemental oxygen&#xD;
&#xD;
          -  Patients who are on daily proton pump inhibitor therapy must be able to discontinue&#xD;
             use or only require use of antacid or hydrogen (H2) antagonist intermittently;&#xD;
             patients who require daily administration of proton pump inhibitor, H2 antagonist, or&#xD;
             pancreatic enzymes are not eligible; intermittent uses of antacids or H2 antagonists&#xD;
             are allowed&#xD;
&#xD;
          -  Systemic infection requiring IV antibiotic therapy within 14 days preceding the first&#xD;
             dose of study drug, or other severe infection&#xD;
&#xD;
          -  Myocardial infarction within 6 months prior to enrollment or has New York Heart&#xD;
             Association (NYHA) class III or IV heart failure, uncontrolled angina, severe&#xD;
             uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute&#xD;
             ischemia or active conduction system abnormalities (except asymptomatic patients with&#xD;
             a pacemaker with electrocardiogram (ECG) changes reflecting conduction abnormalities&#xD;
             secondary to the pacemaker); prior to study entry, any ECG abnormality at screening&#xD;
             has to be documented by the investigator as not medically relevant&#xD;
&#xD;
          -  Female subject is pregnant or breast-feeding; confirmation that the subject is not&#xD;
             pregnant must be established by a negative serum Œ≤-human chorionic gonadotropin&#xD;
             (Œ≤-hCG) pregnancy test result obtained during screening; pregnancy testing is not&#xD;
             required for post-menopausal or surgically sterilized women&#xD;
&#xD;
          -  Patient has received other investigational drugs with 14 days before enrollment&#xD;
&#xD;
          -  Serious medical or psychiatric illness likely to interfere with participation in this&#xD;
             clinical study&#xD;
&#xD;
          -  Other severe acute or chronic medical or psychiatric condition, including uncontrolled&#xD;
             diabetes, malabsorption, resection of the pancreas or upper small bowel, requirement&#xD;
             for pancreatic enzymes, any condition that would modify small bowel absorption of oral&#xD;
             medications, or laboratory abnormality that may increase the risk associated with&#xD;
             study participation or investigational product administration or may interfere with&#xD;
             the interpretation of study results and, in the judgment of the investigator, would&#xD;
             make the patient inappropriate for enrollment in this study&#xD;
&#xD;
          -  Diagnosed or treated for another malignancy within 3 years of enrollment, with the&#xD;
             exception of complete resection of basal cell carcinoma or squamous cell carcinoma of&#xD;
             the skin, an in situ malignancy, or low-risk prostate cancer after curative therapy&#xD;
&#xD;
          -  Treatment with clinically significant enzyme inducers, such as the enzyme- inducing&#xD;
             antiepileptic drugs phenytoin, carbamazepine or phenobarbital, or rifampin, rifabutin,&#xD;
             rifapentine or St. John's wort within 14 days prior to the first dose of MLN8237 and&#xD;
             during the study&#xD;
&#xD;
          -  Patients with a corrected QT interval (QTc) at baseline of &gt; 450 milliseconds or other&#xD;
             factors that increase the risk of QT prolongation or arrhythmic events (i.e., heart&#xD;
             failure, hypokalemia with potassium &lt; 3.5 despite supplementation, family history of&#xD;
             long QT syndrome) should be excluded&#xD;
&#xD;
          -  Patients who require use of a concomitant medication that can prolong the QT interval&#xD;
             and who are unable to discontinue use of this medication during the study period are&#xD;
             excluded&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kristie Blum, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ohio State University Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://cancer.osu.edu</url>
    <description>The Jamesline</description>
  </link>
  <verification_date>May 2018</verification_date>
  <study_first_submitted>March 13, 2013</study_first_submitted>
  <study_first_submitted_qc>March 14, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 15, 2013</study_first_posted>
  <results_first_submitted>March 21, 2017</results_first_submitted>
  <results_first_submitted_qc>May 3, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">June 6, 2018</results_first_posted>
  <last_update_submitted>May 3, 2018</last_update_submitted>
  <last_update_submitted_qc>May 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MLN8237</keyword>
  <keyword>B-cell Non Hodgkin Lymphoma</keyword>
  <keyword>Rituximab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Burkitt Lymphoma</mesh_term>
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Follicular</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Mantle-Cell</mesh_term>
    <mesh_term>Lymphoma, B-Cell, Marginal Zone</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
    <mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Cohort A (Alisertib, Rituximab)</title>
          <description>Patients receive alisertib PO BID on days 1-7. Patients unable to achieve CR after course 4 also receive rituximab IV on day 1 of courses 5-12. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.&#xD;
alisertib: Given PO&#xD;
rituximab: Given IV&#xD;
laboratory biomarker analysis: Laboratory correlative studies will be performed</description>
        </group>
        <group group_id="P2">
          <title>Cohort B (Alisertib, Rituximab)</title>
          <description>Patients receive alisertib as in Cohort A. Patients achieving SD or asymptomatic progressive disease after 2 courses also receive rituximab IV on day 1 of courses 3-10. Patients unable to achieve CR by course 4, receive rituximab as in Cohort A. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.&#xD;
alisertib: Given PO&#xD;
rituximab: Given IV&#xD;
laboratory biomarker analysis: Laboratory correlative studies will be performed</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cohort A (Alisertib, Rituximab)</title>
          <description>Patients receive alisertib PO BID on days 1-7. Patients unable to achieve CR after course 4 also receive rituximab IV on day 1 of courses 5-12. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.&#xD;
alisertib: Given PO&#xD;
rituximab: Given IV&#xD;
laboratory biomarker analysis: Laboratory correlative studies will be performed</description>
        </group>
        <group group_id="B2">
          <title>Cohort B (Alisertib, Rituximab)</title>
          <description>Patients receive alisertib as in Cohort A. Patients achieving SD or asymptomatic progressive disease after 2 courses also receive rituximab IV on day 1 of courses 3-10. Patients unable to achieve CR by course 4, receive rituximab as in Cohort A. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.&#xD;
alisertib: Given PO&#xD;
rituximab: Given IV&#xD;
laboratory biomarker analysis: Laboratory correlative studies will be performed</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
            <count group_id="B2" value="13"/>
            <count group_id="B3" value="14"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="77" lower_limit="77" upper_limit="77"/>
                    <measurement group_id="B2" value="58" lower_limit="35" upper_limit="73"/>
                    <measurement group_id="B3" value="67.5" lower_limit="35" upper_limit="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>patients</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Best Overall Response Rate (ORR) to Alisertib Alone</title>
        <description>Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.</description>
        <time_frame>Up to 18 weeks (6 courses)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cohort A (Alisertib, Rituximab)</title>
            <description>Patients receive alisertib PO BID on days 1-7. Patients unable to achieve CR after course 4 also receive rituximab IV on day 1 of courses 5-12. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.&#xD;
alisertib: Given PO&#xD;
rituximab: Given IV&#xD;
laboratory biomarker analysis: Laboratory correlative studies will be performed</description>
          </group>
          <group group_id="O2">
            <title>Cohort B (Alisertib, Rituximab)</title>
            <description>Patients receive alisertib as in Cohort A. Patients achieving SD or asymptomatic progressive disease after 2 courses also receive rituximab IV on day 1 of courses 3-10. Patients unable to achieve CR by course 4, receive rituximab as in Cohort A. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.&#xD;
alisertib: Given PO&#xD;
rituximab: Given IV&#xD;
laboratory biomarker analysis: Laboratory correlative studies will be performed</description>
          </group>
        </group_list>
        <measure>
          <title>Best Overall Response Rate (ORR) to Alisertib Alone</title>
          <description>Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.</description>
          <units>percentage of patients</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="NA" upper_limit="NA">95% Confidence Interval was incalculable due to an insufficient number of events</measurement>
                    <measurement group_id="O2" value="15" lower_limit="2" upper_limit="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Response Rate (ORR)</title>
        <description>Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.</description>
        <time_frame>6 weeks (2 courses)</time_frame>
        <population>2 course endpoints only apply to Cohort B, since Cohort B only received 2 courses of the interested drug</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort A (Alisertib, Rituximab)</title>
            <description>Patients receive alisertib PO BID on days 1-7. Patients unable to achieve CR after course 4 also receive rituximab IV on day 1 of courses 5-12. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.&#xD;
alisertib: Given PO&#xD;
rituximab: Given IV&#xD;
laboratory biomarker analysis: Laboratory correlative studies will be performed</description>
          </group>
          <group group_id="O2">
            <title>Cohort B (Alisertib, Rituximab)</title>
            <description>Patients receive alisertib as in Cohort A. Patients achieving SD or asymptomatic progressive disease after 2 courses also receive rituximab IV on day 1 of courses 3-10. Patients unable to achieve CR by course 4, receive rituximab as in Cohort A. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.&#xD;
alisertib: Given PO&#xD;
rituximab: Given IV&#xD;
laboratory biomarker analysis: Laboratory correlative studies will be performed</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Response Rate (ORR)</title>
          <description>Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.</description>
          <population>2 course endpoints only apply to Cohort B, since Cohort B only received 2 courses of the interested drug</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="8" lower_limit="0" upper_limit="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Response Rate (ORR)</title>
        <description>95% binomial confidence intervals calculated.</description>
        <time_frame>12 weeks (4 courses)</time_frame>
        <population>Data were not collected from the single participant in the &quot;Cohort A (Alisertib, Rituximab)&quot; Arm/Group therfore the 95% Confidence Interval was incalculable due to an insufficient number of events</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort A (Alisertib, Rituximab)</title>
            <description>Patients receive alisertib PO BID on days 1-7. Patients unable to achieve CR after course 4 also receive rituximab IV on day 1 of courses 5-12. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.&#xD;
alisertib: Given PO&#xD;
rituximab: Given IV&#xD;
laboratory biomarker analysis: Laboratory correlative studies will be performed</description>
          </group>
          <group group_id="O2">
            <title>Cohort B (Alisertib, Rituximab)</title>
            <description>Patients receive alisertib as in Cohort A. Patients achieving SD or asymptomatic progressive disease after 2 courses also receive rituximab IV on day 1 of courses 3-10. Patients unable to achieve CR by course 4, receive rituximab as in Cohort A. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.&#xD;
alisertib: Given PO&#xD;
rituximab: Given IV&#xD;
laboratory biomarker analysis: Laboratory correlative studies will be performed</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Response Rate (ORR)</title>
          <description>95% binomial confidence intervals calculated.</description>
          <population>Data were not collected from the single participant in the &quot;Cohort A (Alisertib, Rituximab)&quot; Arm/Group therfore the 95% Confidence Interval was incalculable due to an insufficient number of events</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Response Rate(ORR)</title>
        <description>Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.</description>
        <time_frame>18 weeks (6 courses)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cohort A (Alisertib, Rituximab)</title>
            <description>Patients receive alisertib PO BID on days 1-7. Patients unable to achieve CR after course 4 also receive rituximab IV on day 1 of courses 5-12. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.&#xD;
alisertib: Given PO&#xD;
rituximab: Given IV&#xD;
laboratory biomarker analysis: Laboratory correlative studies will be performed</description>
          </group>
          <group group_id="O2">
            <title>Cohort B (Alisertib, Rituximab)</title>
            <description>Patients receive alisertib as in Cohort A. Patients achieving SD or asymptomatic progressive disease after 2 courses also receive rituximab IV on day 1 of courses 3-10. Patients unable to achieve CR by course 4, receive rituximab as in Cohort A. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.&#xD;
alisertib: Given PO&#xD;
rituximab: Given IV&#xD;
laboratory biomarker analysis: Laboratory correlative studies will be performed</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Response Rate(ORR)</title>
          <description>Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.</description>
          <units>percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Complete Response Rate (CR)</title>
        <description>Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.</description>
        <time_frame>6 weeks (2 courses)</time_frame>
        <population>2 course endpoints only apply to Cohort B, since Cohort B only received 2 courses of the interested drug</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort A (Alisertib, Rituximab)</title>
            <description>Patients receive alisertib PO BID on days 1-7. Patients unable to achieve CR after course 4 also receive rituximab IV on day 1 of courses 5-12. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.&#xD;
alisertib: Given PO&#xD;
rituximab: Given IV&#xD;
laboratory biomarker analysis: Laboratory correlative studies will be performed</description>
          </group>
          <group group_id="O2">
            <title>Cohort B (Alisertib, Rituximab)</title>
            <description>Patients receive alisertib as in Cohort A. Patients achieving SD or asymptomatic progressive disease after 2 courses also receive rituximab IV on day 1 of courses 3-10. Patients unable to achieve CR by course 4, receive rituximab as in Cohort A. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.&#xD;
alisertib: Given PO&#xD;
rituximab: Given IV&#xD;
laboratory biomarker analysis: Laboratory correlative studies will be performed</description>
          </group>
        </group_list>
        <measure>
          <title>Complete Response Rate (CR)</title>
          <description>Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.</description>
          <population>2 course endpoints only apply to Cohort B, since Cohort B only received 2 courses of the interested drug</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Complete Response Rate</title>
        <description>Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.</description>
        <time_frame>12 weeks (4 courses)</time_frame>
        <population>data was not collected for participants in Cohort B (Alisertib, Rituximab)</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort A (Alisertib, Rituximab)</title>
            <description>Patients receive alisertib PO BID on days 1-7. Patients unable to achieve CR after course 4 also receive rituximab IV on day 1 of courses 5-12. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.&#xD;
alisertib: Given PO&#xD;
rituximab: Given IV&#xD;
laboratory biomarker analysis: Laboratory correlative studies will be performed</description>
          </group>
          <group group_id="O2">
            <title>Cohort B (Alisertib, Rituximab)</title>
            <description>Patients receive alisertib as in Cohort A. Patients achieving SD or asymptomatic progressive disease after 2 courses also receive rituximab IV on day 1 of courses 3-10. Patients unable to achieve CR by course 4, receive rituximab as in Cohort A. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.&#xD;
alisertib: Given PO&#xD;
rituximab: Given IV&#xD;
laboratory biomarker analysis: Laboratory correlative studies will be performed</description>
          </group>
        </group_list>
        <measure>
          <title>Complete Response Rate</title>
          <description>Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.</description>
          <population>data was not collected for participants in Cohort B (Alisertib, Rituximab)</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">95% Confidence Interval was incalculable due to an insufficient number of events</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <description>Graphically summarized using the methods of Kaplan and Meier.</description>
        <time_frame>Time from study entry to the time of death due to any cause, assessed up to 1 year</time_frame>
        <population>data was not collected for participants in Cohort A</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort A (Alisertib, Rituximab)</title>
            <description>Patients receive alisertib PO BID on days 1-7. Patients unable to achieve CR after course 4 also receive rituximab IV on day 1 of courses 5-12. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.&#xD;
alisertib: Given PO&#xD;
rituximab: Given IV&#xD;
laboratory biomarker analysis: Laboratory correlative studies will be performed</description>
          </group>
          <group group_id="O2">
            <title>Cohort B (Alisertib, Rituximab)</title>
            <description>Patients receive alisertib as in Cohort A. Patients achieving SD or asymptomatic progressive disease after 2 courses also receive rituximab IV on day 1 of courses 3-10. Patients unable to achieve CR by course 4, receive rituximab as in Cohort A. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.&#xD;
alisertib: Given PO&#xD;
rituximab: Given IV&#xD;
laboratory biomarker analysis: Laboratory correlative studies will be performed</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>Graphically summarized using the methods of Kaplan and Meier.</description>
          <population>data was not collected for participants in Cohort A</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="3.1" lower_limit="1.7" upper_limit="27.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-free Survival</title>
        <description>Graphically summarized using the methods of Kaplan and Meier.</description>
        <time_frame>Time from study entry to the time of progression and/or death, assessed up to 1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cohort A (Alisertib, Rituximab)</title>
            <description>Patients receive alisertib PO BID on days 1-7. Patients unable to achieve CR after course 4 also receive rituximab IV on day 1 of courses 5-12. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.&#xD;
alisertib: Given PO&#xD;
rituximab: Given IV&#xD;
laboratory biomarker analysis: Laboratory correlative studies will be performed</description>
          </group>
          <group group_id="O2">
            <title>Cohort B (Alisertib, Rituximab)</title>
            <description>Patients receive alisertib as in Cohort A. Patients achieving SD or asymptomatic progressive disease after 2 courses also receive rituximab IV on day 1 of courses 3-10. Patients unable to achieve CR by course 4, receive rituximab as in Cohort A. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.&#xD;
alisertib: Given PO&#xD;
rituximab: Given IV&#xD;
laboratory biomarker analysis: Laboratory correlative studies will be performed</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival</title>
          <description>Graphically summarized using the methods of Kaplan and Meier.</description>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="NA" upper_limit="NA">95% Confidence Interval was incalculable due to an insufficient number of events</measurement>
                    <measurement group_id="O2" value="1.2" lower_limit=".8" upper_limit="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Complete Response Rate</title>
        <description>Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.</description>
        <time_frame>18 weeks (6 courses)</time_frame>
        <population>The data was not collected and analyzed for this outcome measure</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort A (Alisertib, Rituximab)</title>
            <description>Patients receive alisertib PO BID on days 1-7. Patients unable to achieve CR after course 4 also receive rituximab IV on day 1 of courses 5-12. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.&#xD;
alisertib: Given PO&#xD;
rituximab: Given IV&#xD;
laboratory biomarker analysis: Laboratory correlative studies will be performed</description>
          </group>
          <group group_id="O2">
            <title>Cohort B (Alisertib, Rituximab)</title>
            <description>Patients receive alisertib as in Cohort A. Patients achieving SD or asymptomatic progressive disease after 2 courses also receive rituximab IV on day 1 of courses 3-10. Patients unable to achieve CR by course 4, receive rituximab as in Cohort A. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.&#xD;
alisertib: Given PO&#xD;
rituximab: Given IV&#xD;
laboratory biomarker analysis: Laboratory correlative studies will be performed</description>
          </group>
        </group_list>
        <measure>
          <title>Complete Response Rate</title>
          <description>Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.</description>
          <population>The data was not collected and analyzed for this outcome measure</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>The National Cancer Institutes Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 was used to grade toxicities for patients</desc>
      <group_list>
        <group group_id="E1">
          <title>Cohort A</title>
          <description>Cohort A: Patients receive alisertib PO BID on days 1-7. Patients unable to achieve CR after course 4 also receive rituximab IV on day 1 of courses 5-12. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.</description>
        </group>
        <group group_id="E2">
          <title>Cohort B</title>
          <description>Cohort B: Patients receive alisertib as in Cohort A. Patients achieving SD or asymptomatic progressive disease after 2 courses also receive rituximab IV on day 1 of courses 3-10. Patients unable to achieve CR by course 4, receive rituximab as in Cohort A. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE version 4.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Duodenal obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Generalized muscle weakness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Neoplasms benign</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Cystitis</sub_title>
                <description>noninfective</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Hematuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Thromboembolic event</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE version 4.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Febrile Neutropenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Study had slow patient enrollment and was discontinued after only 14 patients were enrolled.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Kristie Blum, MD</name_or_title>
      <organization>The Ohio State University James Comprehensive Cancer Center</organization>
      <phone>614-293-7807</phone>
      <email>Kristie.Blum@osumc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

